Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors

Cancer

Volumn 92, Issue 4, 2001, Pages 787-795

  Gras, Esther ^a   Cortes, Joan ^a   Diez, Orland ^a   Alonso, Carmen ^a   Matias Guiu, Xavier ^a,b   Baiget, Montserrat ^a   Prat, Jaime ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

BRCA 2; Chromosome 13q; Loss of heterozygosity; Ovarian tumors; Serous carcinoma; Sporadic ovarian carcinoma

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; MICROSATELLITE DNA;

ARTICLE; BREAST CARCINOMA; CHROMOSOME 13Q; CONTROLLED STUDY; DNA METHYLATION; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

BRCA2 PROTEIN; CARCINOMA; CHROMOSOMES, HUMAN, PAIR 13; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PEDIGREE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION FACTORS;

EID: 0035880744     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010815)92:4<787::AID-CNCR1384>3.0.CO;2-4     Document Type: Article

References (57)

1. Consistent loss of the wild-type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13
2. Detection of allelic losses on 17q12-q21 chromosomal region in benign lesions and malignant tumors occurring in a familial context
3. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome
4. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer
5. Loss of heterozygosity in sporadic breast tumors at the BRCA2 locus on chromosome 13q12-13
6. At lest four different chromosomal regions are involved in loss of heterozygosity in human breast carcinoma
7. Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms
8. Allelic imbalance on chromosome 13q: Evidence for the involvement of BRCA2 and RB1 in sporadic breast cancer
9. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression
10. Loss of heterozygosity in human ductal breast tumors indicates a recessive mutation on chromosome 13
11. Allelic loss in ovarian cancer
12. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer
13. BRCA1 mutations in primary breast and ovarian carcinomas
14. A somatic BRCA1 mutation in an ovarian tumour
15. BRCA2 mutations in primary breast and ovarian cancers
16. Somatic mutations in the BRCA1 gene sporadic ovarian tumours
17. Mutation analysis in the BRCA2 gene in primary breast cancers
18. Mutations of the BRCA2 gene in ovarian carcinomas
19. Low incidence of BRCA2 mutations in breast carcinoma and other cancers
20. Alterations in DNA methylation: A fundamental aspect of neoplasia
21. Horsthemke. Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma
22. Silencing of the VHL tumor-supressor gene by DNA methylation in renal carcinoma
23. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
24. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair defective human tumor cell lines
25. Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: Association with carcinomas with serous differentiation
26. Promoter hypermethylation is a cause of BRCA1 inactivation in sporadic breast and ovarian tumors
27. The 1993-94 Genethon human genetic linkage map
28. Identification of the breast cancer susceptibility gene BRCA2
29. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
30. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13
31. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds
32. Double indemnity: p53, BRCA and cancer
33. The BRCA2 gene product functionally interacts with p53 and Rad 51
34. Multiple possible sites of BRCA2 interacting with DNA repair protein RAD51
35. Gatekeepers and caretakers
36. Association of BRCA1 with Rad51 in mitotic and meiotic cells
37. Mutations in the BRCA1-associated ring domain (BARD1) gene in primary breast, ovarian and uterine cancers
38. BRCA1, BRCA2 and DNA damage response: Collision or collusion?
39. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families
40. Linkage of early-onset familial breast cancer to chromosome 17q21
41. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
42. Evidence for involvement of BRCA1 in sporadic breast carcinomas
43. Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype
44. Genetic heterogeneity of breast-ovarian cancer revisited
45. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families
46. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes
47. Allelotype of human ovarian cancer
48. Inactivation of glutatione S-transferase PI gene by promoter hypermethylation in human neoplasia
49. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas
50. Hypermethylation-associated inactivation indicates a tumor supressor role for p15INKHB
51. 5′ CpG methylation is associated with transcriptional silencing of the tumour supressor p16/CDKN2/ MTS1 in human cancers
52. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis
53. Silencing of the E-cadherin invasion-supressor gene by CpG methylation in human carcinomas
54. Isolation and initial characterization of the BRCA-2 promoter
55. Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers
56. Methylation meets acetylation
57. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex